CTOs on the Move

Oncocyte

www.oncocyte.com

 
Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oncocyte.com
  • 1010, Atlantic Avenue
    Alameda, CA USA 94501
  • Phone: 949.409.7600

Executives

Name Title Contact Details

Similar Companies

Shasqi

Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.

Kymanox

Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.

Ganeden Biotech

Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Devices

At Molecular Devices, we enable our customers to unravel the complexity of biological systems. Our innovative analytical solutions for cell and protein biology enable our customers to see more, do more, and know more, and to answer life`s most important questions. We are one of the world`s leading providers of high-performance bioanalytical measurement solutions for life science research, pharmaceutical and biotherapeutic development. With over 130,000 placements in laboratories around the world, our instruments have catalyzed brilliant scientific research described in over 25,000 peer reviewed publications. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products empower scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Our headquarters are in Silicon Valley, the hub of technology and innovation, with offices around the globe employing close to 1,000 highly skilled and passionate associates.

Coya Therapeutics

The company`s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an `off the shelf` approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson`s, Alzheimer`s, FTD and autoimmune diseases.